Navigation Links
New protocols improve detection of microRNAs for diagnosis
Date:12/7/2011

Philadelphia, PA, -- MicroRNAs (miRNAs) that regulate processes including fertilization, development, and aging show promise as biomarkers of disease. They can be collected from routinely collected fluids such as blood, saliva, and urine. However, a number of factors can interfere with the accuracy of miRNA tests. In a study published online today in the Journal of Molecular Diagnostics, a group of researchers provide clear procedures for the collection and analysis of miRNA, significantly improving their diagnostic accuracy.

"Our study demonstrates that inherent differences in biological samples and the methods used to collect and analyze them can dramatically affect the detection and quantitation of microRNAs," reports lead investigator Dominik M. Duelli, PhD, Department of Cellular and Molecular Pharmacology, Chicago Medical School at Rosalind Franklin University of Medicine and Science. "We developed measures to overcome the interfering activities and improved the sensitivity of miRNA detection up to 30-fold."

Over 1,000 miRNAs exist in the human body. Deregulation of specific miRNAs is associated with disease. Measuring the amount of miRNAs in body fluids can aid in the diagnosis of disease or conditions such as pregnancy. Dr. Duelli and his colleagues quantified two miRNAs: miR-16, which acts as a tumor suppressor and is deregulated or lost in some cancers, including breast cancer; and miR-223, which has been implicated in pregnancy and other conditions, as well as in some malignant diseases.

"A fundamental challenge to making microRNA diagnostics broadly available has been the inability to isolate enough high quality material to analyze. Our paper outlines ways of effectively collecting blood plasma samples, thus bringing us one step closer to the goal of making [miRNA] disease diagnostics a reality," adds co-investigator Sarah Linnstaedt, PhD, of Duke University.

The authors found that the choice of blood collection tube affects quantitation. Traditional green-top heparin tubes interfered nearly completely with miRNA detection. Grey-top tubes containing the anticoagulant sodium fluoride and potassium oxalate (NaF/KOx) provided the best results. Although miR-16 is about 500 times more abundant in blood plasma than miR-223, the results for both were similar, indicating that the differences in detection resulting from the choice of collection method apply to other miRNAs. Furthermore, collection of miR-223 in serum yielded more variable results, signifying that for some miRNAs, analysis of blood in plasma form is preferred.

The study indicated that natural components of blood plasma co-purify with miRNAs, interfering with their detection. The authors identified extra steps in purification, and the ideal dilution level, to reduce the interference. "Although counterintuitive, by reducing the starting material, inhibitors were presumed to be diluted below a threshold of interference. Careful titration of starting material yields more accurate miRNA quantitation," explains Dr. Duelli. In another approach, the authors avoided the problem of contamination by combining an enzyme that overcomes plasma inhibitors with standard enzymes to increase the sensitivity of miRNA detection by about 30-fold.

Finally, the authors observed that differences in plasma composition among individual donors yield different miRNA measurements. "These results raise the possibility that factors including diet, exercise, circadian rhythms, and seasons, which alter the blood chemistry, might affect miRNA detection and quantitation," says Dr. Duelli.

"The implications of this work are that without consideration of the variables we have identified, miRNA quantitation of human samples may not be reliable for the purpose of biomarker development. We provide approaches that enable faithful quantitation of miRNA abundance in body fluid," concludes Dr. Duelli.


'/>"/>
Contact: David Sampson
jmdmedia@elsevier.com
215-239-3171
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. Transcriptome analysis, organ culture methods featured in Cold Spring Harbor Protocols
2. Standardized protocols would greatly enhance clinical and research potential of BTMs
3. Imaging in depth: 3-dimensional microscopy featured in Cold Spring Harbor Protocols
4. Cold Spring Harbor Protocols features chromosomal rearrangement, gene copy number methods
5. Zinc finger nuclease, immunoprecipitation methods featured in Cold Spring Harbor Protocols
6. Cold Spring Harbor Protocols features Drosophila neurobiology methods
7. Electrophoresis of RNA, avian imaging featured in Junes Cold Spring Harbor Protocols
8. Mays Cold Spring Harbor Protocols features plant gene expression methods, Xenopus imaging
9. Tissue engineering, imaging neuronal circuits featured in Cold Spring Harbor Protocols
10. Protein-bait interactions, display libraries featured in Cold Spring Harbor Protocols
11. High-throughput analysis of gene regulation, DNA synthesis in Cold Spring Harbor Protocols
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)...   TapImmune, Inc. (NASDAQ: ... the development of innovative peptide and gene-based immunotherapeutics ... metastatic disease, announced today it has successfully completed ... second clinical lot of TPIV 200, the company,s ... manufactured vaccine product will be used to supply ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent market research, business ... new report, Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027 ... ... Revenues of ... for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine vision, force sensing ...
(Date:1/26/2017)... Jan. 26, 2017  Crossmatch, a leading provider of ... solution aimed at combatting fraud, waste and abuse in ... at the Action on Disaster Relief conference in ... for UN agencies and foreign assistance organizations throughout ... and abuse are a largely unacknowledged problem in the ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... , February 27, 2017 A Europe-wide ... indicated that researchers using animals in their research treat them with ... 26 countries, and detailed analysis of the results indicates that there ... to put into practice the principles of the 3Rs ... ...
(Date:2/27/2017)... CITY, Calif. , Feb. 27, 2017 /PRNewswire/ ... pharmaceutical company focused on the development and commercialization ... acute pain, announced today the U.S. Food and ... Drug Application (NDA) under section 505(b)(2) for DSUVIA™ ... the treatment of patients with moderate-to-severe acute pain ...
(Date:2/27/2017)... PRINCETON, N.J. and HAMILTON, ... Advaxis, Inc. (NASDAQ: ADXS ) ... late-stage biopharmaceutical companies focused on developing cancer immunotherapies, ... license to develop a novel cancer immunotherapy agent ... technology with SELLAS, patented WT1 targeted heteroclitic peptide ...
(Date:2/27/2017)... , ... February 27, 2017 , ... In starting a ... advice of his grandfather, “Hire for attitude. Train for skill.” , In keeping with ... linebacker Jevohn Miller as a salesman. Zamzow is hoping to replicate the practice throughout ...
Breaking Biology Technology: